期刊文献+

奥匹卡朋的合成工艺改进 被引量:1

Improvement in the Synthesis of Opicapone
下载PDF
导出
摘要 以3,4-二羟基-5-硝基苯甲酸为起始物料,经苄基醚化、酯化、酯基水解得3,4-二苄氧基-5-硝基苯甲酸,再与2,5-二氯-N-羟基-4,6-二甲基烟碱偕胺肟发生缩合后关环、氧化、脱苄基制得帕金森症治疗药物奥匹卡朋,总收率27.2%,纯度达99.3%,改进后的路线原料来源方便,操作简单,具有工业化生产前景。 As a drug for the treatment of Parkinson's disease, Opicapone was obtained using 3,4-dihydroxyl-5- nitryl-benzoic acid as the starting material followed by etherifieation, esterification, hydrolysis, condensation reaction with 2,5-dichlorine-N-hydroxyl--4,6-dimethyl-nicotineamidoxime, cyclization, oxidation, and debenzylation. The overall yield was 27.2% with a purity of 99.3%. This synthetic process is simple and easy for industrial operation with high yield and wide raw material sources.
出处 《精细化工中间体》 CAS 2016年第2期41-43,共3页 Fine Chemical Intermediates
关键词 3 4-二羟基-5-硝基苯甲酸 奥匹卡朋 帕金森症 3,4-dihydroxyl-5-nitryl-benzoic acid opicapone parkinson's disease
  • 相关文献

参考文献8

  • 1汤森路透.疾病综述:帕金森病[J].国际药学研究杂志,2015,42(3):338-345. 被引量:23
  • 2韩燕.COMT抑制剂:一种新的治疗帕金森病的药物[J].国外医学(老年医学分册),2000,21(1):33-35. 被引量:4
  • 3利尔蒙斯D A.作为COMT抑制剂的硝基儿茶酚衍生物:中国,102816157[P].2006-07-26. 被引量:1
  • 4Laszlo E K, Humberto S F, Leonel T, et al. Discovery of a longacting, peripherally selective inhibitor of catechol-O-methyhransferase[J]. J Med Chem, 2010, 53(8): 3 396-3 411. 被引量:1
  • 5Zhu B T, Ezell E L, Liehr J G. Catechol-O-methyhransferasecatalysed rapid O-methylation of mutagenic flavanoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vitro[J]. J Biol Chem, 1994, 269(1): 292 - 299. 被引量:1
  • 6Russo D. Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor:WO 2013089573 [P]. 2013-06-20. 被引量:1
  • 7Sabine B, Anny C C, Zhu J. Studies on the total syntheis of RP66453: Synthesis of fully functionalized 15-membered biaryl- containing macrocyle[J]. Org Lett, 2001, 3(13): 2 061-2 064. 被引量:1
  • 8Takahiko A, Hajimu H, Shoichiro O. AlCl3-N,N-dimethylaniline: A new benzyl and allyl ether cleavage reagent[J]. Tetrahedron Lett, 1991, 32(10): 1 321-1 324. 被引量:1

二级参考文献21

  • 1Marsden CD. Parkinson's disease. J Nurosurg Psychiatry, 1994;57:672~681 被引量:1
  • 2Stanley F. Tolcapone:COMT inhibition for the treatment of Parkmson's disease. Neurology,1998;50 (Suppl 5):S1~S2 被引量:1
  • 3Sage JI. Mark MH. Basic meehanisms of motor fluetuations. Neurology,1994:44(Suupl 6):S10~S14 被引量:1
  • 4Maninez Martin P. Brien CF. Extending levodopa action:COMT inhibition. Neurology,1998;50(Suppl 6):S27~S32,discussion S44 被引量:1
  • 5Rajput AH, Martin W, Saint Hllaire MH et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon:a double-blind, placeho-controlled,multi-center trial. Neurology,1997;49:1066~1071 被引量:1
  • 6Matthias C, Kurth Charles H. COMT inhibition: A new treatment strategy for Parkinson's disease. Neurology,1998;50(Suppl 5) S3~S14 被引量:1
  • 7Kaakkola S, Gordin A, Mannisto PT. General properties and clinical possibilities of new selective inhibition of catechol-O-methyhmnsferase, Genpharmacol, 1994;25:813~824 被引量:1
  • 8Dingemanse J, Jorga KM, Zutcher G et al. Pharmacokinetic-pharmacodynamic intraction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Pharmacol,1995:40:253~262 被引量:1
  • 9Karin MC, Jorga. Pharmacokinetics,pharmacedynamics, and tolerability of tolcapone: A review of early studies in volunteers. Neurology,1998;50(Suppl 5): S31~S38 被引量:1
  • 10Waters CH, Kurth M, Bailey P et al.Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. Neurology, 1997:49:665~671 被引量:1

共引文献25

同被引文献2

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部